A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses

NCT07633288 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Viral Infection

Interventions

DRUG: AP1189, 100 mg
DRUG: Placebo

Sponsor

SynAct Pharma Aps